CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
SEATTLE, May 30, 2023 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) which was scheduled for June 21, 2023, and has withdrawn the … Read more